Randomized, double blind, parallel group, repeat dose pharmacokinetic and pharmacodynamic study of four doses of ATL-962 (40mg, 80mg, 120mg, 240mg) in otherwise-healthy obese volunteers.

Trial Profile

Randomized, double blind, parallel group, repeat dose pharmacokinetic and pharmacodynamic study of four doses of ATL-962 (40mg, 80mg, 120mg, 240mg) in otherwise-healthy obese volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2011

At a glance

  • Drugs Cetilistat (Primary)
  • Indications Obesity
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 06 Sep 2006 Status change
    • 04 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top